Needham & Company LLC Boosts OrthoPediatrics (NASDAQ:KIDS) Price Target to $42.00

OrthoPediatrics (NASDAQ:KIDS) had its price target hoisted by Needham & Company LLC from $37.00 to $42.00 in a research note issued to investors on Tuesday morning, Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

A number of other analysts have also commented on the company. JMP Securities reiterated a market outperform rating and set a $50.00 price target on shares of OrthoPediatrics in a report on Tuesday. Truist Financial lowered OrthoPediatrics from a buy rating to a hold rating and dropped their price target for the stock from $39.00 to $31.00 in a report on Thursday, January 25th.

OrthoPediatrics Trading Down 7.2 %

Shares of KIDS stock traded down $2.40 during trading hours on Tuesday, reaching $31.09. The company had a trading volume of 151,608 shares, compared to its average volume of 190,036. OrthoPediatrics has a 12 month low of $23.10 and a 12 month high of $48.47. The company has a quick ratio of 2.90, a current ratio of 5.44 and a debt-to-equity ratio of 0.03. The business has a fifty day simple moving average of $29.09 and a 200-day simple moving average of $29.15.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Wednesday, March 6th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.05. The business had revenue of $37.61 million for the quarter, compared to analyst estimates of $37.59 million. OrthoPediatrics had a negative return on equity of 5.10% and a negative net margin of 13.58%. Analysts anticipate that OrthoPediatrics will post -1.34 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Fred Hite sold 3,195 shares of OrthoPediatrics stock in a transaction on Monday, March 11th. The stock was sold at an average price of $27.59, for a total value of $88,150.05. Following the completion of the transaction, the chief financial officer now directly owns 94,072 shares in the company, valued at $2,595,446.48. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CEO David R. Bailey sold 3,213 shares of OrthoPediatrics stock in a transaction on Monday, March 11th. The stock was sold at an average price of $27.59, for a total value of $88,646.67. Following the completion of the transaction, the chief executive officer now directly owns 139,384 shares in the company, valued at $3,845,604.56. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Fred Hite sold 3,195 shares of OrthoPediatrics stock in a transaction on Monday, March 11th. The shares were sold at an average price of $27.59, for a total value of $88,150.05. Following the sale, the chief financial officer now directly owns 94,072 shares of the company’s stock, valued at approximately $2,595,446.48. The disclosure for this sale can be found here. Insiders sold 17,253 shares of company stock valued at $477,375 over the last ninety days. 31.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On OrthoPediatrics

Large investors have recently added to or reduced their stakes in the business. CWM LLC boosted its stake in OrthoPediatrics by 16,283.3% during the fourth quarter. CWM LLC now owns 983 shares of the company’s stock valued at $32,000 after buying an additional 977 shares during the period. RiverPark Advisors LLC bought a new stake in OrthoPediatrics during the third quarter valued at $35,000. International Assets Investment Management LLC boosted its stake in OrthoPediatrics by 3,151.4% during the fourth quarter. International Assets Investment Management LLC now owns 1,203 shares of the company’s stock valued at $37,000 after buying an additional 1,166 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in OrthoPediatrics by 136.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,341 shares of the company’s stock valued at $107,000 after buying an additional 1,927 shares during the period. Finally, State Board of Administration of Florida Retirement System bought a new stake in OrthoPediatrics during the first quarter valued at $178,000. Institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.